» Articles » PMID: 29602702

Human Papillomavirus Vaccination Coverage in Luxembourg - Implications of Lowering and Restricting Target Age Groups

Overview
Journal Vaccine
Date 2018 Apr 1
PMID 29602702
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In Luxembourg, a national Human Papillomavirus (HPV) vaccination programme was introduced in 2008, targeting 12-17 year old girls offering a choice of bivalent or quadrivalent vaccine free of charge. In 2015, the programme was changed offering the bivalent vaccine only to 11-13 year old girls. The aim of this study was to evaluate the HPV vaccination coverage, to assess the impact of age target changes and compare vaccination coverage to other European countries.

Methods: Anonymous HPV vaccination records consisting of individual vaccine doses obtained free of charge in pharmacies between 2008 and 2016 were extracted from the Luxembourgish Social Security database. Additional aggregate tables by nationality and municipality were analysed.

Results: Of the target cohort of 39,610 girls born between 1991 and 2003 residing in Luxembourg, 24,550 (62.0%) subjects obtained at least one dose, 22,082 (55.7%) obtained at least two doses, and 17,197 (43.4%) obtained three doses of HPV vaccine. The mean age at first dose was 13.7 years during 2008-14 and 12.7 years in 2016 after the age target change. Coverage varied significantly by nationality (p < 0.0001): Portuguese (80%), former Yugoslavs (74%), Luxembourgish (54%), Belgian (52%), German (47%), French (39%) and other nationalities (51%). Coverage varied also by geographical region, with lower rates (<50%) noted in some Northern and Central areas of Luxembourg (range: 38% to 78%).

Conclusion: Overall HPV vaccination coverage in Luxembourg is moderate and varied by nationality and region. The policy changes in 2015 did not have a substantial impact except lowering age at initiating vaccination. Options to improve coverage deserve further investigation.

Citing Articles

The Effect of Interventions Based on the Information-Motivation-Behavioral Skills Model on the Human Papillomavirus Vaccination Rate Among 11-13-Year-Old Girls in Central and Western China: Protocol for a Randomized Controlled Trial.

Jing S, Wu Y, Dai Z, Tang S, Su X, Qiao Y JMIR Res Protoc. 2024; 13:e58873.

PMID: 39560975 PMC: 11615549. DOI: 10.2196/58873.


Characterization and Diversity of 243 Complete Human Papillomavirus Genomes in Cervical Swabs Using Next Generation Sequencing.

Latsuzbaia A, Wienecke-Baldacchino A, Tapp J, Arbyn M, Karabegovic I, Chen Z Viruses. 2020; 12(12).

PMID: 33327447 PMC: 7764970. DOI: 10.3390/v12121437.


Progress in Vaccination of Prophylactic Human Papillomavirus Vaccine.

Zhou X, Sun L, Yao X, Li G, Wang Y, Lin Y Front Immunol. 2020; 11:1434.

PMID: 32754157 PMC: 7365840. DOI: 10.3389/fimmu.2020.01434.


HPV vaccination and sexual behaviour in healthcare seeking young women in Luxembourg.

Soudeyns C, Speybroeck N, Brisson M, Mossong J, Latsuzbaia A PeerJ. 2020; 8:e8516.

PMID: 32095350 PMC: 7017793. DOI: 10.7717/peerj.8516.


Human Papillomavirus Vaccines: Successes and Future Challenges.

Perez S, Zimet G, Tatar O, Stupiansky N, Fisher W, Rosberger Z Drugs. 2018; 78(14):1385-1396.

PMID: 30269207 DOI: 10.1007/s40265-018-0975-6.